BiotechTube

Saracatinib + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteosarcoma

Conditions

Osteosarcoma

Trial Timeline

Mar 1, 2009 → Dec 1, 2017

NCT ID
NCT00752206

About Saracatinib + Placebo

Saracatinib + Placebo is a phase 2 stage product being developed by AstraZeneca for Osteosarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00752206. Target conditions include Osteosarcoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02085603Phase 2Completed
NCT00752206Phase 2Terminated

Competing Products

18 competing products in Osteosarcoma

See all competitors
ProductCompanyStageHype Score
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
33
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
52
PemetrexedEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
Olaparib + CeralasertibAstraZenecaPhase 2
52
robatumumabMerckPhase 2
52
PembrolizumabMerckPhase 2
52
pazopanibNovartisPhase 2
52
AvelumabPfizerPhase 2
51
Nivolumab + AzacitidineBristol Myers SquibbPhase 1
32
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
51
Cisplatin liposomalInsmedPhase 1/2
38
CabozantinibIpsenPhase 2
49
Sm-EDTMPJazz PharmaceuticalsPhase 2
49
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).Lantheus HoldingsPhase 1/2
38
REOLYSIN®Oncolytics BiotechPhase 2
44

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85